DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prospective Analgesic Compound Efficacy (PACE) Study

Information source: Express Specialty Pharmacy
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Arthritis; Tendonitis; Gout; Radiculopathy; Muscle Spasms; Synovitis; Migraine; Headache

Intervention: baclofen 2% (Drug); Bupivacaine hydrochloride 1% (Drug); Cyclobenzaprine hydrochloride 2% (Drug); Diclofenac Sodium 3% (Drug); Flurbiprofen 10% (Drug); Gabapentin 6% (Drug); Ketamine 10% (Drug); Lidocaine 2% (Drug); Prilocaine 2.5% (Drug); Meloxicam 0.09% (Drug); Sumatriptan 5% (Drug); Tizanidine 0.1% (Drug); Topiramate 2.5% (Drug); Capsaicin, USP 0.0375% (Drug); Menthol, NF 5.00 % (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Express Specialty Pharmacy

Official(s) and/or principal investigator(s):
Kate McLellan, PhD, Study Director, Affiliation: KM Clinical

Overall contact:
Kate McLellan, PhD, Phone: 6197270373, Email: kate@kmclinical.com


A 24-week observational prospective study on the efficacy of topical non-steroidal anti-inflammatory drugs for the relief of pain.

Clinical Details

Official title: Prospective Analgesic Compound Efficacy (PACE) Study

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: subjective pain control as measured by a 10-point visual analog scale (VAS).

Detailed description: Objectives The primary objective is the change in pain levels as measured by a 10-point visual analog scale (VAS). Secondary objectives are changes in concomitant pain medication use, quality of life, and patient satisfaction with pain management. Design and Outcomes The study will be conducted at 1 family practice medical clinic in Houston, TX. Patients will be prescribed a pain cream compound based on their symptoms and medical history. Periodic surveys will be administered and concomitant medications recorded to ascertain current pain levels, quality of life, and satisfaction with current pain levels. Blood tests will be performed to monitor liver and kidney function. Interventions and Duration Non-steroidal anti-inflammatory steroid (NSAID) topical cream will be prescribed to patients presenting with pain. For patients with localized pain, they will also be prescribed a transdermal analgesic patch to wear at the site of pain. Subjects will be followed for 24-weeks with surveys administered at baseline, and 1, 2, 4, 8, 12, 16, 20, and 24-weeks after baseline with blood tests performed at 12 and 24-weeks. If patients do not find satisfactory pain relief or experience undesirable side effects from the cream they will be given a prescription for an oral NSAID at anytime during the 24-week observation. Sample Size and Population 500 patients will be enrolled in the study between March 1, 2015 and March 1, 2017. Subjects will be screened from the patient population at 1960 Family Practice, 837 Cupress Creek Parkway, Suite 105, Houston Texas. Subjects will have presented with a primary complaint of pain. Subjects will be stratified by the following medical indications; Arthritis Muscle Spasms Tendonitis Idiopathic Gout Synovitis Radiculopathy Migraine


Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- 4. 1.1 Primary complaint or clinical findings of arthritis, tendonitis, gout,

synovitis, radiculopathy, muscle spasms, migraines, and/or idiopathic pain. 4. 1.2 No new pain medications of any kind in the last 4 weeks. 4. 1.3 Between the ages of 18-85yrs. Exclusion Criteria:

- 4. 2.1 Current or history of disease or disorders of the liver, kidneys,

gastrointestinal system, or cardiovascular system. 4. 2.2 Blood test indicating kidney, liver, or cardiovascular function outside of normal clinically accepted ranges. Blood test must be performed in the last 7 days. 4. 2.3 Broken or inflamed skin, burns, open wounds, atopic dermatitis or eczema in the area of pain where the compound cream and transdermal patch would be applied. 4. 2.4 Women who are pregnant, nursing, or planning to become pregnant in the next 24-weeks. 4. 2.5 Allergy/sensitivity to study drugs or their formulations. 4. 2.6 Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 4. 2.7 Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 14 days prior to study entry. 4. 2.8 Inability or unwillingness of subject to give written informed consent.

Locations and Contacts

Kate McLellan, PhD, Phone: 6197270373, Email: kate@kmclinical.com

Additional Information

Starting date: April 2015
Last updated: March 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017